Drug Trial Radar · NCT05020015
A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Last checked: Nov 19, 2026Latest source record: Mar 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
27
Actual
Start
Nov 12, 2021
Primary completion
Jun 16, 2024
Study completion Dec 20, 2038
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Aug 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study has 2 parts. The main aim of Part 1 is to check for side effects from TAK-007 in adults with relapsed or refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL), The main aim of Part 2 is to learn whether lymphoma disease responds to treatment with TAK-007 in adults with r/r B-cell NHL or iNHL. Participants will receive 3 days of chemotherapy to reduce a type of white blood cells called lymphocytes, in the blood. This is called lymphodepleting chemotherapy (LDC) or lymphodepletion. After LDC, patients will receive a single injection of TAK-007 or three weekly injections of TAK-007 (multi-dose injection). After this, participants will regularly visit the clinic for check-ups.
Conditions
- Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Interventions
TAK-007Biological
TAK-007 intravenous injection.
Chemotherapy AgentsDrug
Fludarabine and cyclophosphamide as per standard of care.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 24 months
- Number of Participants With Clinically Significant Changes in Laboratory ParametersTime frame: Up to 24 months
- Number of Participants With Notable Changes in Vital SignsTime frame: Up to 24 months
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Cedars Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
Los Angeles, California
MedStar Georgetown University Medical Center
Washington D.C., District of Columbia
Sylvester Comprehensive Cancer Center University of Miami Hospitals and Clinics
Miami, Florida
Northside Hospital
Atlanta, Georgia
Northwestern Memorial Hospital
Chicago, Illinois
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan
Columbia University Medical Center
New York, New York
Montefiore Medical Center
The Bronx, New York
DUHS Duke Blood Cancer Center
Durham, North Carolina
Oregon Health and Science University
Portland, Oregon
Thomas Jefferson University Sidney Kimmer Cancer Center, Clinical Research Organization
Philadelphia, Pennsylvania
Saint Davids South Austin Medical Center
Austin, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas
University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.